Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Status:
Unknown status
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Mantle cell lymphoma (MCL) remains difficult to treat by standard treatment approaches. Novel
drugs have shown promising results in early clinical evaluations. In the current trial, we
investigate a combination of bortezomib (a proteasome inhibitor), rituximab (a monoclonal
antibody), and dexamethasone in patients with MCL, who have already been pretreated by
standard chemotherapy and show again signs of disease progression. The study objectives
include remission rates, safety of this drug combination, and survival time.